Burosumab, a human monoclonal anti-FGF23 antibody, was recently approved as a specific therapy for XLH, data from phase 2 and 3 trials report overall safety and efficacy. The gene discussed is FGF23; the disease is X-linked dominant hypophosphatemic rickets.